Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

20167,113 citationsJournal Articlebronze Open Access

Authors

Steven P. Marso · The University of Texas Southwestern Medical Center

Gilbert H. Daniels · Massachusetts General Hospital

Kirstine Brown‐Frandsen · Novo Nordisk (Denmark)

Peter Lommer Kristensen · Novo Nordisk (Denmark)

Johannes F.E. Mann · Friedrich-Alexander-Universität Erlangen-Nürnberg

Michael A. Nauck · Ruhr University Bochum

Steven E. Nissen

Abstract

In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048.).

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Pancreatic function and diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 375, Issue 4, pp. 311-322

DOI: 10.1056/nejmoa1603827

Field-Weighted Citation Impact: 618.87